Literature DB >> 33172542

Anti-inflammatory mechanisms of suppressors of cytokine signaling target ROS via NRF-2/thioredoxin induction and inflammasome activation in macrophages.

Ga-Young Kim, Hana Jeong, Hye-Young Yoon, Hye-Min Yoo, JaeYoung Lee, Seok Hee Park, Choong-Eun Lee1.   

Abstract

Suppressors of cytokine signaling (SOCS) exhibit diverse anti-inflammatory effects. Since ROS acts as a critical mediator of inflammation, we have investigated the anti-inflammatory mechanisms of SOCS via ROS regulation in monocytic/macrophagic cells. Using PMA-differentiated monocytic cell lines and primary BMDMs transduced with SOCS1 or shSOCS1, the LPS/TLR4-induced inflammatory signaling was investigated by analyzing the levels of intracellular ROS, antioxidant factors, inflammasome activation, and pro-inflammatory cytokines.The levels of LPS-induced ROS and the production of pro-inflammatory cytokines were notably down-regulated by SOCS1 and up-regulated by shSOCS1 in an NAC-sensitive manner. SOCS1 up-regulated an ROS-scavenging protein, thioredoxin, via enhanced expression and binding of NRF-2 to the thioredoxin promoter. SOCS3 exhibited similar effects on NRF-2/thioredoxin induction, and ROS downregulation, resulting in the suppression of inflammatory cytokines. Notably thioredoxin ablation promoted NLRP3 inflammasome activation and restored the SOCS1-mediated inhibition of ROS and cytokine synthesis induced by LPS. The results demonstrate that the anti-inflammatory mechanisms of SOCS1 and SOCS3 in macrophages are mediated via NRF-2-mediated thioredoxin upregulation resulting in the downregulation of ROS signal.Thus, our study supports the anti-oxidant role of SOCS1 and SOCS3 in the exquisite regulation of macrophage activation under oxidative stress.

Entities:  

Year:  2020        PMID: 33172542

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  8 in total

Review 1.  Therapeutic potential of Nrf-2 pathway in the treatment of diabetic neuropathy and nephropathy.

Authors:  Amit Gupta; Tapan Behl; Aayush Sehgal; Saurabh Bhatia; Dharmender Jaglan; Simona Bungau
Journal:  Mol Biol Rep       Date:  2021-03-22       Impact factor: 2.316

Review 2.  Prospect of thioredoxin as a possibly effective tool to combat OSAHS.

Authors:  Ye Pan; You Lu; Jie-Dong Zhou; Cui-Xue Wang; Jin-Quan Wang; Atsushi Fukunaga; Junji Yodoi; Hai Tian
Journal:  Sleep Breath       Date:  2022-05-27       Impact factor: 2.816

3.  FGF21 ameliorates hepatic fibrosis by multiple mechanisms.

Authors:  Fanrui Meng; Mir Hassan Khoso; Kai Kang; Qi He; Yukai Cao; Xinghao Jiang; Wei Xiao; Deshan Li
Journal:  Mol Biol Rep       Date:  2021-09-18       Impact factor: 2.316

4.  Nrf2 Regulates CHI3L1 to Suppress Inflammation and Improve Post-Traumatic Osteoarthritis.

Authors:  Yang Song; Dake Hao; Huan Jiang; Mingguang Huang; Qingjun Du; Yi Lin; Fei Liu; Bin Chen
Journal:  J Inflamm Res       Date:  2021-08-24

5.  Nrf2 protects against cerebral ischemia-reperfusion injury by suppressing programmed necrosis and inflammatory signaling pathways.

Authors:  Weiwei Chen; Xue Teng; Hongmei Ding; Zhiyuan Xie; Ping Cheng; Zhihan Liu; Tao Feng; Xia Zhang; Wenjuan Huang; Deqin Geng
Journal:  Ann Transl Med       Date:  2022-03

6.  Identification of differently expressed mRNAs by peripheral blood mononuclear cells in Vogt-Koyanagi-Harada disease.

Authors:  Yujing Li; Guannan Su; Fanfan Huang; Ying Zhu; Xiang Luo; Aize Kijlstra; Peizeng Yang
Journal:  Genes Dis       Date:  2021-06-30

7.  NRF2 activation by 2-methoxycinnamaldehyde attenuates inflammatory responses in macrophages via enhancing autophagy flux.

Authors:  Bo-Sung Kim; Minwook Shin; Kyu-Won Kim; Ki-Tae Ha; Sung-Jin Bae
Journal:  BMB Rep       Date:  2022-08       Impact factor: 5.041

8.  SOCS3 Attenuates Dexamethasone-Induced M2 Polarization by Down-Regulation of GILZ via ROS- and p38 MAPK-Dependent Pathways.

Authors:  Hana Jeong; Hyeyoung Yoon; Yerin Lee; Jun Tae Kim; Moses Yang; Gayoung Kim; Bom Jung; Seok Hee Park; Choong-Eun Lee
Journal:  Immune Netw       Date:  2022-06-13       Impact factor: 5.851

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.